{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:13Z","timestamp":1791357433887,"version":"4.3.1"},"reference-count":84,"publisher":"Royal College of Psychiatrists","issue":"S52","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":2984,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Depot antipsychotics are widely used in clinical practice. Long-acting formulations of second-generation antipsychotics are now being developed and introduced.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To review the pharmacology, pharmacokinetics and adverse effect profiles of currently available antipsychotic long-acting injections (LAIs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>The psychopharmacological properties of first- and second-generation antipsychotic LAIs are reviewed using data available up to October 2008.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>First-generation antipsychotic (FGA) LAIs are associated with a high rate of acute and chronic movement disorders. Risperidone LAI is better tolerated in this respect, but is associated with hyperprolactinaemia and weight gain. Olanzapine LAI causes weight gain and other metabolic effects but appears not to be associated with an important incidence of movement disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Dosing of LAIs is complicated by delayed release of drug, changes in plasma levels without change in dose, and by the lack of data establishing clear dose requirements. All LAIs offer the prospect of assured adherence (although patients may still default on treatment) but their use is complicated by adverse effects, complex pharmacokinetics and confusion over dose\u2013response relationships.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.195.52.s13","type":"journal-article","created":{"date-parts":[[2009,10,31]],"date-time":"2009-10-31T23:47:48Z","timestamp":1257032868000},"page":"s13-s19","source":"Crossref","is-referenced-by-count":94,"title":["Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review"],"prefix":"10.1192","volume":"195","author":[{"given":"David","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000245972_ref45","article-title":"Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives","volume":"67","author":"Moller","year":"2007","journal-title":"Drugs"},{"key":"S0007125000245972_ref43","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0512"},{"key":"S0007125000245972_ref52","doi-asserted-by":"publisher","DOI":"10.1007\/BF00589893"},{"key":"S0007125000245972_ref40","article-title":"Depot pipotiazine 1970\u20131982: a review","volume":"44","author":"Burch","year":"1983","journal-title":"J Clin Psychiatry"},{"key":"S0007125000245972_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(89)90013-4"},{"key":"S0007125000245972_ref28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1176\/ajp.147.5.672a","article-title":"Use of extremely low doses of fluphenazine decanoate","volume":"147","author":"Geller","year":"1990","journal-title":"Am J Psychiatry"},{"key":"S0007125000245972_ref26","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-198704000-00008"},{"key":"S0007125000245972_ref69","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1985.tb08537.x"},{"key":"S0007125000245972_ref18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0447.1980.tb07082.x","article-title":"Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels","volume":"279","author":"Jorgensen","year":"1980","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"S0007125000245972_ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1974.tb08889.x"},{"key":"S0007125000245972_ref13","doi-asserted-by":"publisher","DOI":"10.1007\/BF02316862"},{"key":"S0007125000245972_ref29","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1987.01800180028005"},{"key":"S0007125000245972_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(85)90063-0"},{"key":"S0007125000245972_ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb00941.x"},{"key":"S0007125000245972_ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb01045.x"},{"key":"S0007125000245972_ref44","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-6-3"},{"key":"S0007125000245972_ref46","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.6.1125"},{"key":"S0007125000245972_ref32","doi-asserted-by":"publisher","DOI":"10.1192\/pb.29.3.104"},{"key":"S0007125000245972_ref41","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1014290"},{"key":"S0007125000245972_ref4","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.169.5.618"},{"key":"S0007125000245972_ref38","article-title":"Pipotiazine palmitate: an evaluation of a new long acting intramuscular antipsychotic agent in severely ill schizophrenic patients","volume":"36","author":"Gallant","year":"1975","journal-title":"Dis Nerv Syst"},{"key":"S0007125000245972_ref9","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174062"},{"key":"S0007125000245972_ref62","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.123.5.519"},{"key":"S0007125000245972_ref14","article-title":"[Initial results of a pharmacokinetic study of pipothiazine and its palmitic ester (Piportil L4) in a schizophrenic population]","volume":"10","author":"Girard","year":"1984","journal-title":"Encephale"},{"key":"S0007125000245972_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(03)80260-8"},{"key":"S0007125000245972_ref22","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145704004924"},{"key":"S0007125000245972_ref54","article-title":"D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate","volume":"152","author":"Nyberg","year":"1995","journal-title":"Am J Psychiatry"},{"key":"S0007125000245972_ref68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-0447.1980.tb07085.x","article-title":"Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial","volume":"279","author":"Ahlfors","year":"1980","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"S0007125000245972_ref76","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3280119ddb"},{"key":"S0007125000245972_ref39","doi-asserted-by":"publisher","DOI":"10.1185\/03007998609111098"},{"key":"S0007125000245972_ref57","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.3.396"},{"key":"S0007125000245972_ref33","first-page":"S7","article-title":"Minimal effective dose and relapse \u2013 double-blind trial: haloperidol decanoate vs. placebo","volume":"14","author":"Eklund","year":"1991","journal-title":"Clin Neuropharmacol"},{"key":"S0007125000245972_ref24","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.135.2.175"},{"key":"S0007125000245972_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/BF00491981"},{"key":"S0007125000245972_ref19","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174677"},{"key":"S0007125000245972_ref12","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198911000-00005"},{"key":"S0007125000245972_ref10","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1987.tb02175.x"},{"key":"S0007125000245972_ref80","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.4.361"},{"key":"S0007125000245972_ref42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1991.tb01414.x"},{"key":"S0007125000245972_ref36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1985.tb08538.x"},{"key":"S0007125000245972_ref74","volume-title":"Summary of Product Characteristics. Zypadhera 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection","author":"Lilly","year":"2009"},{"key":"S0007125000245972_ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1985.tb08539.x"},{"key":"S0007125000245972_ref53","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830220079011"},{"key":"S0007125000245972_ref20","first-page":"228S","article-title":"Pharmacokinetics (PK) of multiple doses of olanzapine long-acting injection (OLAI), an intramuscular (IM) depot formulation of olanzapine (OLZ), in stabilized patients with schizophrenia","volume":"63","author":"Kurtz","year":"2008","journal-title":"Biol Psychiatry"},{"key":"S0007125000245972_ref47","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.105.017020"},{"key":"S0007125000245972_ref1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199410060-00005"},{"key":"S0007125000245972_ref75","volume-title":"Psychopharmacologic Drugs Advisory Committee Briefing Document. Zyprexa Olanzapine Pamoate (OP) Depot. Olanzapine Long-Acting Injection. Schizophrenia","author":"Lilly","year":"2009"},{"key":"S0007125000245972_ref27","doi-asserted-by":"crossref","DOI":"10.1176\/ajp.156.3.412","article-title":"Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks","volume":"156","author":"Carpenter","year":"1999","journal-title":"Am J Psychiatry"},{"key":"S0007125000245972_ref16","doi-asserted-by":"publisher","DOI":"10.1007\/BF00429723"},{"key":"S0007125000245972_ref31","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.4.554"},{"key":"S0007125000245972_ref2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198510040-00003"},{"key":"S0007125000245972_ref35","article-title":"The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects","volume":"51","author":"Mazure","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"S0007125000245972_ref11","article-title":"Perphenazine decanoate in sesame oil vs. perphenazine enanthate in sesame oil: a comparative study of pharmacokinetic properties and some clinical implications","volume":"322","author":"Knudsen","year":"1985","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"S0007125000245972_ref25","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.151.5.634"},{"key":"S0007125000245972_ref48","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145705006309"},{"key":"S0007125000245972_ref50","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.4.514"},{"key":"S0007125000245972_ref79","doi-asserted-by":"publisher","DOI":"10.1002\/hup.877"},{"key":"S0007125000245972_ref82","doi-asserted-by":"publisher","DOI":"10.1192\/pb.26.5.170"},{"key":"S0007125000245972_ref8","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1017373"},{"key":"S0007125000245972_ref51","article-title":"Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response. A double-blind PET study in schizophrenia","volume":"32","author":"Agid","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"S0007125000245972_ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1802-1"},{"key":"S0007125000245972_ref56","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301409"},{"key":"S0007125000245972_ref58","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.195.52.s20"},{"key":"S0007125000245972_ref59","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.4.290"},{"key":"S0007125000245972_ref60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1986.tb06242.x"},{"key":"S0007125000245972_ref61","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.135.6.515"},{"key":"S0007125000245972_ref63","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198908000-00003"},{"key":"S0007125000245972_ref64","article-title":"A double-blind trial of haloperidol decanoate and pipothiazine palmitate in the maintenance treatment of schizophrenics in a public out-patient clinic","volume":"37","author":"Bechelli","year":"1985","journal-title":"Curr Ther Res"},{"key":"S0007125000245972_ref84","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.10.1079"},{"key":"S0007125000245972_ref65","article-title":"A clinical double-blind comparison between haloperidol decanoate and fluphenazine decanoate","volume":"35","author":"Wistedt","year":"1984","journal-title":"Curr Ther Res"},{"key":"S0007125000245972_ref66","first-page":"15","article-title":"A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients","volume":"1","author":"Wistedt","year":"1986","journal-title":"Int Clin Psychopharmacol"},{"key":"S0007125000245972_ref67","doi-asserted-by":"publisher","DOI":"10.1007\/BF00426949"},{"key":"S0007125000245972_ref70","doi-asserted-by":"crossref","unstructured":"David A , Quraishi S , Rathbone J . Depot perphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst Rev 2005; (3): CD001717.","DOI":"10.1002\/14651858.CD001717.pub2"},{"key":"S0007125000245972_ref71","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1980.tb00602.x"},{"key":"S0007125000245972_ref72","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7002.421"},{"key":"S0007125000245972_ref73","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(08)70643-6"},{"key":"S0007125000245972_ref77","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00980.x"},{"key":"S0007125000245972_ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.03.015"},{"key":"S0007125000245972_ref81","article-title":"Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches","volume":"45","author":"Ereshefsky","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"S0007125000245972_ref83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"S0007125000245972_ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1980.tb00875.x"},{"key":"S0007125000245972_ref49","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0808"},{"key":"S0007125000245972_ref17","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199404000-00008"},{"key":"S0007125000245972_ref15","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363050-00004"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000245972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T11:39:01Z","timestamp":1710675541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000245972\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":84,"journal-issue":{"issue":"S52","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0007125000245972"],"URL":"https:\/\/doi.org\/10.1192\/bjp.195.52.s13","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}